Compagnie Lombard Odier SCmA Sells 4,431 Shares of DexCom, Inc. (NASDAQ:DXCM)

Compagnie Lombard Odier SCmA decreased its holdings in DexCom, Inc. (NASDAQ:DXCM) by 2.8% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 151,283 shares of the medical device company’s stock after selling 4,431 shares during the quarter. Compagnie Lombard Odier SCmA’s holdings in DexCom were worth $10,142,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the business. Team Hewins LLC lifted its position in DexCom by 3.4% in the 1st quarter. Team Hewins LLC now owns 2,555 shares of the medical device company’s stock valued at $354,000 after acquiring an additional 83 shares in the last quarter. Bleakley Financial Group LLC increased its stake in DexCom by 1.3% in the 1st quarter. Bleakley Financial Group LLC now owns 6,856 shares of the medical device company’s stock valued at $951,000 after buying an additional 87 shares during the last quarter. Capital Insight Partners LLC increased its stake in DexCom by 2.5% in the 2nd quarter. Capital Insight Partners LLC now owns 3,690 shares of the medical device company’s stock valued at $418,000 after buying an additional 90 shares during the last quarter. Gulf International Bank UK Ltd increased its stake in DexCom by 0.3% in the 1st quarter. Gulf International Bank UK Ltd now owns 32,075 shares of the medical device company’s stock valued at $4,448,000 after buying an additional 93 shares during the last quarter. Finally, Harbor Investment Advisory LLC increased its stake in DexCom by 13.1% in the 1st quarter. Harbor Investment Advisory LLC now owns 864 shares of the medical device company’s stock valued at $120,000 after buying an additional 100 shares during the last quarter. Institutional investors own 97.75% of the company’s stock.

Insider Buying and Selling at DexCom

In other DexCom news, EVP Michael Jon Brown sold 652 shares of the firm’s stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $69.55, for a total value of $45,346.60. Following the completion of the transaction, the executive vice president now directly owns 66,249 shares of the company’s stock, valued at $4,607,617.95. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other DexCom news, EVP Michael Jon Brown sold 652 shares of the firm’s stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $69.55, for a total value of $45,346.60. Following the completion of the transaction, the executive vice president now directly owns 66,249 shares of the company’s stock, valued at $4,607,617.95. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Jacob Steven Leach sold 746 shares of DexCom stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the sale, the chief operating officer now directly owns 264,915 shares of the company’s stock, valued at $18,318,872.25. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 1,824 shares of company stock valued at $126,390 in the last three months. Company insiders own 0.30% of the company’s stock.

DexCom Stock Performance

DXCM traded down $0.35 on Friday, hitting $69.21. The company’s stock had a trading volume of 3,942,344 shares, compared to its average volume of 3,818,354. The company’s 50 day simple moving average is $70.17 and its 200-day simple moving average is $102.62. The firm has a market cap of $27.52 billion, a P/E ratio of 44.65, a price-to-earnings-growth ratio of 2.16 and a beta of 1.18. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00. The company has a quick ratio of 2.48, a current ratio of 2.82 and a debt-to-equity ratio of 1.00.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, July 25th. The medical device company reported $0.43 EPS for the quarter, topping the consensus estimate of $0.39 by $0.04. The company had revenue of $1 billion during the quarter, compared to the consensus estimate of $1.04 billion. DexCom had a net margin of 16.95% and a return on equity of 31.41%. DexCom’s revenue for the quarter was up 15.3% on a year-over-year basis. During the same period last year, the firm earned $0.34 EPS. Analysts forecast that DexCom, Inc. will post 1.69 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have commented on DXCM shares. Oppenheimer decreased their price objective on shares of DexCom from $150.00 to $115.00 and set an “outperform” rating for the company in a research note on Friday, July 26th. Wells Fargo & Company decreased their price objective on shares of DexCom from $145.00 to $80.00 and set an “overweight” rating for the company in a research note on Friday, July 26th. Baird R W lowered shares of DexCom from a “strong-buy” rating to a “hold” rating in a research note on Friday, July 26th. StockNews.com lowered shares of DexCom from a “buy” rating to a “hold” rating in a research note on Saturday. Finally, BTIG Research decreased their price target on shares of DexCom from $156.00 to $120.00 and set a “buy” rating for the company in a research note on Friday, July 26th. Seven investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $110.69.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.